Research organization, collaborating with the global scientific community to increase survival and enrich quality of life for patients needing cellular therapy. Learn more at cibmtr.org.https://bsky.app/profile/cibmtr.bsky.socialhttps://bsky.app/profile/cibmtr.bsky.social/post/3mvqab7ck7n2dNEW: CIBMTR Research Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report Read more: 🔗pubmed.ncbi.nlm.nih.gov/42416786/17 Sep 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mvqab7ck7n2dhttps://bsky.app/profile/cibmtr.bsky.social/post/3mvnydfss7n22The wait is over. Registration for #Tandem27 is officially open! Join ASTCT and CIBMTR in Orlando, February 17-20, 2027, for the premier event in HCT, cellular therapy, and gene therapy. 📍 Orlando, FL 📅 February 17-20, 2027 Secure your spot today: https://www.tandemmeetings.com/Registration/Registration-Information16 Sep 2026 20:32 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mvnydfss7n22https://bsky.app/profile/cibmtr.bsky.social/post/3mvnfqf3aiw2nCould your research question change practice? Don't miss your chance to shape future research. There's only 1 week left to submit a proposal for consideration for a CIBMTR Working Committee study. 📅 Deadline: Monday, Sept. 21 🔗https://cibmtr.org/CIBMTR/Research/Propose-a-Working-Committee-Study16 Sep 2026 15:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mvnfqf3aiw2nhttps://bsky.app/profile/cibmtr.bsky.social/post/3mv6myxlh4q25NEW: CIBMTR Research Infection burden in mismatched unrelated donor HCT: Results from the ACCESS Trial Read more: 🔗pubmed.ncbi.nlm.nih.gov/42448319/10 Sep 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mv6myxlh4q25https://bsky.app/profile/cibmtr.bsky.social/post/3mv3shy4mbp25💡 Your next research idea could help shape the future of transplantation and cellular therapy. CIBMTR is accepting Working Committee Study proposals from investigators interested in leading impactful observational research. 📅 Deadline: Monday, Sept. 21 Submit today: https://cibmtr.org/CIBMTR/Research/Propose-a-Working-Committee-Study09 Sep 2026 15:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mv3shy4mbp25https://bsky.app/profile/cibmtr.bsky.social/post/3mumzqcc4ap2gVisit our Study Summaries page to find what you need—clinical trials and trusted education tools, all in one place. New summaries are added regularly! Explore: cibmtr.org/summaries03 Sep 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mumzqcc4ap2ghttps://bsky.app/profile/cibmtr.bsky.social/post/3mumpoh3iip2jHave a research question that could advance the field of cellular therapy? Submit a CIBMTR Working Committee study proposal for consideration at the 2027 Tandem Meetings. 📅 Deadline: Monday, Sept. 21 🔗 https://cibmtr.org/CIBMTR/Research/Propose-a-Working-Committee-Study03 Sep 2026 15:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mumpoh3iip2jhttps://bsky.app/profile/cibmtr.bsky.social/post/3mukjbqvpff2kAbstract submission for #Tandem27 is now open! ASTCT and CIBMTR invite you to share your research with your HCT, cell, and gene therapy colleagues in Orlando, FL, February 17-20, 2027! Learn more https://www.tandemmeetings.com/Abstr.../Abstract-Information @astct.bsky.social02 Sep 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mukjbqvpff2khttps://bsky.app/profile/cibmtr.bsky.social/post/3muhyslvrev2wNEW: BMT CTN Research CD8+CD38+ T cells identify functional high-risk multiple myeloma after autologous transplant: BTM CTN 0702 correlates Read more: 🔗 https://ashpublications.org/bloodneoplasia/article/doi/10.1016/j.bneo.2026.100221/567209/CD8-CD38-T-cells-Identify-Functional-High-Risk01 Sep 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3muhyslvrev2whttps://bsky.app/profile/cibmtr.bsky.social/post/3mu3ghuobs426NEW: BMT CTN Research TITE-safety: A robust time-to-event safety monitoring approach for clinical trials Read more: 🔗pubmed.ncbi.nlm.nih.gov/42201841/27 Aug 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mu3ghuobs426https://bsky.app/profile/cibmtr.bsky.social/post/3mtwfkdquxy25NEW: BMT CTN Research Commensurate prior models with random effects for interval-censored data to accommodate historical controls Read more: 🔗https://www.tandfonline.com/doi/full/10.1080/03610918.2025.259395025 Aug 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mtwfkdquxy25https://bsky.app/profile/cibmtr.bsky.social/post/3mtm3c562gd2jAbstract submission for #Tandem27 is now open! ASTCT and CIBMTR invite you to share your research with your HCT, cell, and gene therapy colleagues in Orlando, FL, February 17-20, 2027! Learn more https://www.tandemmeetings.com/Abstr.../Abstract-Information @astct.bsky.social21 Aug 2026 15:30 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mtm3c562gd2jhttps://bsky.app/profile/cibmtr.bsky.social/post/3mtjt7iould2hNEW: CIBMTR Research Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in AML in first complete remission: CIBMTR analysis Read more: 🔗pubmed.ncbi.nlm.nih.gov/42206435/20 Aug 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mtjt7iould2hhttps://bsky.app/profile/cibmtr.bsky.social/post/3mtesbmwtlr2zClear, simple research—our Study Summaries break down complex topics into easy-to-understand insights, helping patients feel informed and confident. Explore: cibmtr.org/summaries18 Aug 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mtesbmwtlr2zhttps://bsky.app/profile/cibmtr.bsky.social/post/3mteix2ejav25Clinical trial for mismatched transplant helps more people. Read about this CIBMTR study to learn more: https://cibmtr.org/Patient-Summaries/Clinical-trial-for-mismatched-transplant-helps-more-people.htm18 Aug 2026 15:13 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mteix2ejav25https://bsky.app/profile/cibmtr.bsky.social/post/3msy7x3hp7e2vNEW: CIBMTR Research IMPACT for patients with inborn errors of immunity from the Primary Immune Deficiency Treatment Consortium Read more: 🔗pubmed.ncbi.nlm.nih.gov/42242424/13 Aug 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3msy7x3hp7e2vhttps://bsky.app/profile/cibmtr.bsky.social/post/3mst6z5aauw22Staying up to date is simple. Sort Study Summaries by date to see the latest findings and newly added studies. Explore what’s new: cibmtr.org/summaries11 Aug 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mst6z5aauw22https://bsky.app/profile/cibmtr.bsky.social/post/3msgmolg5f62eNEW: CIBMTR Research Comparison of fludarabine versus bendamustine as a lymphodepleting chemotherapy prior to CAR T for large cell lymphoma Read more: 🔗pubmed.ncbi.nlm.nih.gov/42341926/06 Aug 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3msgmolg5f62ehttps://bsky.app/profile/cibmtr.bsky.social/post/3msdz3joimk2yCIBMTR and the MCW Division of Hematology and Oncology invite applications for a faculty position as a CIBMTR Senior Scientific Director. Learn more about and apply for this important position: https://mcw.wd503.myworkdayjobs.com/en-US/ExternalCareers/job/Faculty--CIBMTR-Scientific-Director_JR100330-105 Aug 2026 17:04 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3msdz3joimk2yhttps://bsky.app/profile/cibmtr.bsky.social/post/3msblr5iazq2pTake a look—filter our Study Summaries by disease or condition. Quickly explore plain-language info on lymphoma, multiple myeloma, sickle cell disease, and more: cibmtr.org/summaries04 Aug 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3msblr5iazq2phttps://bsky.app/profile/cibmtr.bsky.social/post/3msbbp3m4cq2y🔬 What's new at CIBMTR? The August 2026 Newsletter is here! Explore research highlights from our working committees, updates on adoptive cellular therapies & gene therapy reporting, 2025 US Summary Slides, and a preview of #Tandem27. 📬 https://cibmtr.org/CIBMTR/About/News/Newsletters/August-2026-Newsletter04 Aug 2026 15:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3msbbp3m4cq2yhttps://bsky.app/profile/cibmtr.bsky.social/post/3mruzgilyov2wNEW: CIBMTR Research Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR analysis Read more: 🔗pubmed.ncbi.nlm.nih.gov/42364732/30 Jul 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mruzgilyov2whttps://bsky.app/profile/cibmtr.bsky.social/post/3mrpyidqkzb2wIt’s easy to explore our Study Summaries page. Browse by category and quickly find plain-language research summaries—in a clear, user-friendly format. Check it out: cibmtr.org/summaries28 Jul 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mrpyidqkzb2whttps://bsky.app/profile/cibmtr.bsky.social/post/3mravp6dalt2wNEW: CIBMTR Research Quantile regression of the relationship between demographic factors and leukocyte telomere length, measured by Southern blot and qPCR Read more: 🔗pubmed.ncbi.nlm.nih.gov/41619133/22 Jul 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mravp6dalt2whttps://bsky.app/profile/cibmtr.bsky.social/post/3mr3uqsplgm2oNEW: CIBMTR Research Recommendations for HLA genotyping data standards and clinical laboratory staffing considerations Read more: 🔗 pubmed.ncbi.nlm.nih.gov/42007733/20 Jul 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mr3uqsplgm2ohttps://bsky.app/profile/cibmtr.bsky.social/post/3mqude52lw525Need more transplant resources? Our Study Summaries page now links to clinical trial summaries and education tools to support every step of the journey. Explore more ➡️ cibmtr.org/summaries17 Jul 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mqude52lw525https://bsky.app/profile/cibmtr.bsky.social/post/3mqkbitb4kh2nNEW: BMT CTN Research Antigen-specific T cell responses to SARS-CoV-2 vaccination after HCT or CAR T-cell therapy Read more: 🔗pubmed.ncbi.nlm.nih.gov/41941698/13 Jul 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mqkbitb4kh2nhttps://bsky.app/profile/cibmtr.bsky.social/post/3mqa7naqvxd2bNEW: CIBMTR Research Patients with MDS/MPN have higher rates of relapse following allogeneic HCT compared to those with MDS: A Brazilian SBTMO/CIBMTR registry analysis Read more: 🔗pubmed.ncbi.nlm.nih.gov/42032308/09 Jul 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mqa7naqvxd2bhttps://bsky.app/profile/cibmtr.bsky.social/post/3mq36pd6mqd2vNEW: CIBMTR Research Optimal donor selection for transplant to reduce GVHD risk and augment graft-versus-malignancy efficacy Read more: 🔗pubmed.ncbi.nlm.nih.gov/42060959/07 Jul 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mq36pd6mqd2vhttps://bsky.app/profile/cibmtr.bsky.social/post/3mpm3vfmwes2lNEW: CIBMTR Research Factors associated with receipt of allogeneic HCT and NMDP donor search in older adults with AML Read more: 🔗pubmed.ncbi.nlm.nih.gov/42069181/01 Jul 2026 18:00 +0000at://did:plc:zy3fnnflddaknkoh7pfyfjee/app.bsky.feed.post/3mpm3vfmwes2l